Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)’s share price shot up 3.5% during trading on Friday . The company traded as high as $14.40 and last traded at $14.17, with a volume of 61,023 shares. The stock had previously closed at $13.69.

A number of brokerages recently commented on SNDX. Zacks Investment Research cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $24.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $25.00.

The company’s 50 day moving average price is $12.93 and its 200-day moving average price is $13.17. The firm’s market cap is $251.62 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. Equities analysts predict that Syndax Pharmaceuticals Inc. will post ($3.01) EPS for the current year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.